
- •Apothecary
- •History
- •Other Mentions In Creative Literature
- •Noted Apothecaries
- •See also
- •References
- •Overview
- •Etymology
- •Function
- •Examples
- •See also
- •References
- •Clinical pharmacy
- •[Edit] See also
- •[Edit] References
- •[Edit] External links
- •Compounding
- •History
- •New England Compounding Center incident
- •Roles During research and development
- •Patients with unique or unusual medication needs
- •Personalized medicine and polypharmacy
- •Recent trends
- •Regulation in the United States
- •Analogy to "off-label" use
- •Drug testing and reporting of incidents
- •Criticism
- •Regulation in Australia
- •See also
- •References
- •External links
- •Consultant pharmacist
- •United States
- •United Kingdom
- •See also
- •External links
- •Etymology
- •Medication
- •Spiritual and religious use
- •Self-improvement
- •Recreational drug use
- •Administering drugs
- •See also
- •References
- •Health care
- •Health care delivery
- •Primary care
- •Secondary Care
- •Tertiary care
- •Quaternary care
- •Home and community care
- •Related sectors
- •Health system
- •Health care industry
- •Health care research
- •Health care financing
- •Health care administration and regulation
- •Health information technology
- •See also
- •Herbalism
- •History
- •Ancient times
- •Middle Ages
- •Early modern era
- •Modern herbal medicine
- •Biological background
- •Clinical tests
- •Prevalence of use
- •Herbal preparations
- •Practitioners
- •Government regulations
- •Traditional herbal medicine systems
- •Herbal philosophy and spiritual practices
- •Uses of herbal medicines by animals
- •Extinction of medicinal plant species
- •See also
- •References
- •Further reading
- •History of pharmacy
- •Prehistoric pharmacy
- •Antiquity
- •Middle Ages
- •See also
- •References
- •Hospice
- •History Early development
- •Rise of the modern hospice movement
- •Hospice care
- •North America Canada
- •United States
- •United Kingdom
- •Other nations
- •See also
- •Further reading
- •External links
- •Hospital pharmacy
- •Sterile production
- •See also
- •External links
- •Hospital
- •Etymology
- •General
- •District
- •Specialized
- •Teaching
- •Clinics
- •Departments
- •History Early examples
- •Roman Empire
- •Medieval Islamic world
- •Medieval Europe
- •Colonial America
- •Modern era
- •Criticism
- •Funding
- •Buildings Architecture
- •See also
- •References
- •Bibliography
- •External links
- •Medical education
- •Entry-level education
- •Postgraduate education
- •Continuing medical education
- •Online learning
- •Example of medical education systems
- •Medical Education Journals
- •See also
- •References
- •External links
- •Medical ethics
- •History
- •Values in medical ethics
- •Autonomy
- •Beneficence
- •Non-Maleficence
- •Double effect
- •Conflicts between autonomy and beneficence/non-maleficence
- •Euthanasia
- •Informed consent
- •Confidentiality
- •Criticisms of orthodox medical ethics
- •Importance of communication
- •Control and resolution
- •Guidelines
- •Ethics committees
- •Medical ethics in an online world
- •Cultural concerns
- •Truth-telling
- •Online business practices
- •Conflicts of interest
- •Referral
- •Vendor relationships
- •Treatment of family members
- •Sexual relationships
- •Futility
- •Sources and references
- •External links
- •Medical psychology
- •Behavioral medicine
- •Certifications
- •References
- •See also
- •External links
- •Institutions
- •Branches
- •Basic sciences
- •'Medicine' as a specialty
- •Diagnostic specialties
- •Other major specialties
- •Interdisciplinary fields
- •Education
- •Medical ethics
- •Legal controls
- •Criticism of modern medicine
- •Honors and awards
- •History
- •Ancient world
- •Middle ages
- •Patron saints
- •Nobel Prize in Physiology or Medicine
- •Background
- •Nomination and selection
- •Diplomas
- •Award money
- •Ceremony and banquet
- •Laureates
- •Time factor and death
- •Controversial inclusions and exclusions
- •Limits on number of awardees
- •Years without awards
- •References
- •Bibliography
- •[Edit] External links
- •Online pharmacy
- •Home delivery
- •Risks and concerns
- •Discussion
- •International consumers
- •U.S. Consumers
- •Overseas online pharmacies and u.S. Law
- •Enforcement
- •Mail fraud
- •Uk consumers
- •See also
- •References
- •External links
- •Pharmacist
- •Nature of the work
- •Education and credentialing
- •Practice specialization
- •Training and practice by country
- •Australia
- •Japan History
- •Contemporary
- •Tanzania
- •United Kingdom
- •Education and registration
- •Vietnam
- •United States
- •Pharmacy School Accreditation
- •Education
- •Specialization and credentialing
- •Earnings and wages
- •Noted people who were pharmacists
- •See also
- •References
- •Further reading
- •External links
- •Pharmacognosy
- •Introduction
- •Issues in phytotherapy
- •Constituents and drug synergysm
- •Herb and drug interactions
- •Natural products chemistry
- •Loss of biodiversity
- •Sustainable sources of plant and animal drugs
- •Acceptance in the United States
- •External links
- •References
- •Pharmacology
- •Divisions
- •Environmental pharmacology
- •Scientific background
- •Medicine development and safety testing
- •Drug legislation and safety
- •Education
- •See also
- •Footnotes
- •[Edit] External links
- •Pharmacopoeia
- •Etymology
- •History
- •City pharmacopoeia
- •National pharmacopoeia
- •International pharmacopoeia
- •Medical preparations, uses and dosages
- •See also
- •References
- •External links
- •Pharmacy automation
- •History
- •Chronology
- •Global variations
- •Current state of the industry
- •Technological changes and design improvements
- •Other pharmacy-dispensing concerns besides counting
- •Future development
- •Liquid Oral doses (Childs, aging, oncology...)
- •Repackaging process and stability data
- •See also
- •References
- •External links
- •Videos of robots in action
- •Pharmacy technician
- •See also
- •References
- •External links
- •Pharmacy
- •Disciplines
- •Professionals
- •Pharmacists
- •Pharmacy technicians
- •History
- •Types of pharmacy practice areas
- •Community pharmacy
- •Hospital pharmacy
- •Clinical pharmacy
- •Ambulatory care pharmacy
- •Compounding pharmacy
- •Consultant pharmacy
- •Internet pharmacy
- •Veterinary pharmacy
- •Nuclear pharmacy
- •Military pharmacy
- •Pharmacy informatics
- •Issues in pharmacy Separation of prescribing from dispensing
- •The future of pharmacy
- •Pharmacy journals
- •See also
- •Symbols
- •References
- •External links
- •Philosophy of healthcare
- •Ethics of healthcare
- •Medical ethics
- •Nursing ethics
- •Business ethics
- •Political philosophy of healthcare
- •Patients' Bill of Rights
- •Health insurance
- •Research and scholarship
- •Clinical trials
- •Quality assurance
- •Birth and death Reproductive rights
- •Birth and living
- •Death and dying
- •Role development
- •See also
- •References
- •External links
Recent trends
According to the FDA, the emergence over the past decade of firms with pharmacy licenses making and distributing unapproved new drugs, many of which have sickened and killed numerous patients, in a way that's clearly outside the bounds of traditional pharmacy is of great concern. An FDA spokesperson states, "The methods of these companies seem far more consistent with those of drug manufacturers than with those of retail pharmacies. Some firms make large amounts of compounded drugs that are copies or near copies of FDA-approved, commercially available drugs. Other firms sell to physicians and patients with whom they have only a remote professional relationship."[14]
Regulation in the United States
In the United States, compounding pharmacies are licensed and regulated by their respective state like all other pharmacies. National standards have been created by Pharmacy Compounding Accreditation Board (PCAB).[15]
Compounding pharmacies were the subject of the United States Supreme Court decision Thompson v. Western States Medical Center (535 U.S. 357, 2002),[16] which held that Congressional attempts to restrict advertising by compounding pharmacies were unconstitutional. However, the same statute (FDAMA, amending the FDCA which establishes the FDA) also contained a provision that largely exempted compounded products from the FDA's control by defining many of them as not being "new drugs" for FDA purposes. Since the Supreme Court did not rule on the issue of how broadly to interpret that provision, nor on the issue of whether that provision was "severable" from the struck provision, there remains today a Circuit-split on both of those questions: As of 2008, the 9th Circuit (binding in several western states) holds that the provisions are not severable, and hence the entire FDAMA is void; on the other hand, the 6th Circuit (binding in several southwestern states) holds that the provisions are severable, and hence the non-struck portions of the FDAMA remain intact (including what it interpreted to be a limited exemption from FDA reach for any compounded drugs that meet the requirements given in the statute).
Meanwhile, in Circuits where the FDAMA is void and thus the FDA retains its original reach, the FDA weighs the following (non-exhaustive) mix of factors in deciding whether to "exercise its discretion" to require approval for a custom-compounded drug product, from its 2002 Compliance Policy Guide on the matter:[17]
Compounding in anticipation of receiving prescriptions,
Compounding drugs removed from the market for safety reasons,
Compounding from bulk ingredients not approved by FDA,
Receiving, storing, or using drugs not made in an FDA-registered facility,
Receiving, storing, or using drugs' components not determined to meet compendia requirements,
Using commercial-scale manufacturing or testing equipment,
Compounding for third parties for resale,
Compounding drugs that are essentially the same as commercially available products,
Failing to operate in conformance with applicable state law.
Hence, making truly patient-customized products with particular drug(s)/dosage(s) upon receiving valid prescriptions from a physician is likely to be acceptable, especially if the ingredients are FDA approved, etc.
Also from the 2002 CPG document, the FDA assures compounding pharmacies that its main concern is those who effectively engage in multi-patient "manufacturing" under the guise of compounding. "FDA recognizes that pharmacists traditionally have extemporaneously compounded and manipulated reasonable quantities of human drugs upon receipt of a valid prescription for an individually identified patient from a licensed practitioner. This traditional activity is not the subject of this guidance."[18]